Compounded vs Brand-Name Semaglutide: Cost and Differences

In 2024 this comparison was easy. Branded Wegovy listed above $1,300 a month, compounded semaglutide sold for under $200, and people made the obvious choice.

That arithmetic broke in late 2025 and 2026. Branded self-pay prices came down hard while compounded prices mostly did not, and the gap is now small enough that the honest answer depends on your dose, your coverage, and whether you count the membership fee.

This article lays out both sides with real numbers and a verification date. It is not medical advice, and it does not tell anyone which product to use.

What is the actual difference between the two?

Start with what you are buying, because the price comparison only makes sense afterward.

Brand-name semaglutide means Wegovy (for chronic weight management) or Ozempic (for type 2 diabetes), both made by Novo Nordisk, each now sold as both an injection and a pill. One naming change is worth knowing about: Rybelsus, the oral semaglutide approved for type 2 diabetes in 2019, was reformulated and rebranded as the Ozempic pill, which became available in the U.S. on May 4, 2026 in 1.5 mg, 4 mg, and 9 mg strengths, replacing the 3 mg, 7 mg, and 14 mg Rybelsus tablets [19]. Novo says the new formulation is more bioavailable with the same efficacy and safety profile. If you see Rybelsus and the Ozempic pill quoted as separate products, they are the same molecule under successive names.

All of these went through clinical trials, were reviewed and approved by FDA, and are manufactured under an FDA-approved process in inspected facilities. Wegovy’s weight loss and cardiovascular outcome data come from trials of that specific product.

Compounded semaglutide is semaglutide powder that a pharmacy dissolves and puts into a vial. FDA does not review compounded drugs for safety, effectiveness, or quality before they are marketed [1]. There are no clinical trials of any compounded version. FDA has issued warning letters to companies that described compounded semaglutide as generic, equivalent, or having the same active ingredient with equivalent results, calling those claims false or misleading [1].

Three concrete differences beyond the paperwork:

Delivery device. Branded Wegovy comes in a prefilled pen that delivers a fixed dose when you dial it. Compounded product usually comes in a multi-dose vial you draw from with a syringe. FDA has documented ten-fold overdoses caused by that difference.

Ingredient form. FDA has warned that some compounded and imported products use semaglutide sodium or semaglutide acetate rather than the semaglutide base in approved drugs, and says these are different active ingredients [2].

Extra ingredients. Many compounded products add vitamin B12, glycine, or niacinamide. There is no evidence these improve weight loss.

What does branded semaglutide actually cost now?

These are manufacturer self-pay prices, verified September 14, 2026. They do not require insurance.

Wegovy through NovoCare Pharmacy [3]:

Product	Self-pay price per month
Wegovy pen, 0.25 / 0.5 / 1 / 1.7 / 2.4 mg	$349
Wegovy HD pen, 7.2 mg	$399
Wegovy tablet, 1.5 mg	$149
Wegovy tablet, 4 mg	$199
Wegovy tablet, 9 mg and 25 mg	$299
Introductory offer, first 2 fills of 0.25 and 0.5 mg	$199
Ozempic pen, 0.25 / 0.5 / 1 mg	$349
Ozempic pen, 2 mg	$499
Ozempic pill, 1.5 / 4 / 9 mg	$149 / $199 / $299

One month is defined as one box of four pens or one bottle of 30 tablets. The $199 introductory offer runs through December 31, 2026 for patients new to the program.

Costco Pharmacy through Success by Sesame [4]: Wegovy or Ozempic injections at $349 a month, with $199 a month for the first two months for qualifying new patients, and the Wegovy pill from $149. Requires a Costco membership plus a Sesame care fee of $99 a month, or $59 a month annually, with a member discount.

TrumpRx and the federal pricing agreements [5][6]: under the November 6, 2025 agreements, injectable starter doses were set at about $350 a month on the government portal, trending toward $245 over two years. Medicare and Medicaid prices for Ozempic, Wegovy, Mounjaro, and Zepbound were set at $245, with a $50 Medicare copay. Starter doses of oral obesity products were set at $149 a month.

For comparison, tirzepatide — a different drug, Lilly’s Zepbound and Mounjaro, not semaglutide — sells through LillyDirect from $299 a month for 2.5 mg vials, with $50 knocked off previous self-pay pricing under the same November 2025 agreement [7].

Against those numbers, remember what the list price still is today: Wegovy’s list price is widely reported around $1,350 a month, and that is what an uninsured patient outside these programs, or a plan pricing off the list, is quoted. That number is scheduled to change. On February 24, 2026 Novo Nordisk announced that effective January 1, 2027 the list price (wholesale acquisition cost) of Wegovy injection 2.4 mg and tablets 25 mg, Ozempic injection 0.5 / 1 / 2 mg, and Rybelsus 7 mg and 14 mg all drop to $675 a month — roughly a 50 percent cut for Wegovy and 35 percent for Ozempic [17]. That does not change the self-pay prices above, which are already far below list, but it matters for anyone whose out-of-pocket cost is calculated from list price.

What does compounded semaglutide actually cost?

Harder to pin down, because the advertised number is rarely the number you pay. Here is how the structures work, with 2026 examples.

Medication price plus separate membership. This is the most common structure and the most misleading.

• Zealthy: membership $135 a month after a $39 first month — confirmed in Zealthy’s own press releases — with compounded semaglutide reported around $149 to $151 a month. All-in near $286. The membership is solid; the medication figure is not. zealthy.com was unreachable to us on September 14, 2026, and an earlier 2026 capture puts the medication at $199 instead, so treat the all-in as a range.
• Mochi Health: membership $79 a month ($39 first month in eligible states), compounded semaglutide from $60 a month, or $62 for the pill [8] (verified 2026-09-14 on joinmochi.com). All-in near $139. Mochi’s own banner shows $99 struck through as the former medication price, so any source still quoting $99 is stale.
• Ivim Health: membership $75 a month with the first month free, compounded semaglutide $75 a month on a six-month plan [9] (verified 2026-09-14 on ivimhealth.com). All-in near $150, but only on the six-month commitment.

All-in bundled pricing. Some platforms fold everything into one number. Found’s own pricing page confirms cash plans from $169 a month on a 12-month plan paid up front, or $289 a month month-to-month, medication included and billed per 28-day cycle rather than per calendar month (verified 2026-09-14). Noom runs two separate programs and both are billed as subscriptions, not monthly: the Noom Microdose GLP-1 Rx program is an initial three-week subscription plus four weeks of medication from $79, then $179 a month on a 12-week subscription; the full Noom Med program starts at $149 on the same structure and then runs $299 a month (verified 2026-09-14). Earlier figures of $129 and $279 for Noom, and a $49 microdose entry price, are not on Noom’s pages and have been removed.

Two structural traps sit inside those figures.

Prepay. The lowest monthly numbers almost always require paying six or twelve months up front, which is usually non-refundable. A $75 a month price that requires $900 today is not a $75 a month price in any sense that matters to your budget.

Dose escalation. Some platforms charge a flat rate across the dose ladder; others charge more as your dose goes up. Ask before you start, because the entry price is quoted at the starter dose.

Side-by-side, at realistic totals

All figures verified September 14, 2026. Verify with the provider before acting on any of them; telehealth pricing in this category changes often.

Route	Typical all-in monthly cost	FDA approved?	Notes
Insurance-covered branded	$25 or less in some plans	Yes	Requires coverage plus prior authorization
Medicare GLP-1 Bridge Program, eligible Part D patients	$50 copay	Yes	Runs July 1, 2026 through December 31, 2027; copay sits outside regular Part D
Wegovy pill starter dose + low-cost visit	About $178 ($149 + $29 visit)	Yes	Counsel Health visit fee used as the example
Compounded semaglutide, membership platform	$150 to $290	No	Lowest figures usually require prepay
Wegovy pen via NovoCare	$349, or $199 intro	Yes	Plus a visit fee if you need a prescriber
Costco / Sesame injection	About $408 ($349 + $59 care)	Yes	Costco membership required
Wegovy pen via full-service telehealth	$400 to $500	Yes	Membership plus medication
Wegovy at list price	Around $1,350	Yes	What you avoid by using any of the above

The headline: the Wegovy pill at starter doses plus a cheap visit fee is now competitive with, and sometimes cheaper than, a compounded program. That was not true a year ago.

Why was compounded semaglutide so much cheaper in the first place?

Five reasons, none of which are about the drug being better made.

1. No clinical trials to recover. Novo Nordisk spent years and enormous sums on the semaglutide trial program. A compounder pays none of that.
2. No approval process. No application, no review.
3. No pen device. A prefilled injector is an engineered product with its own manufacturing cost. A vial is a vial.
4. Cheap bulk ingredient. Compounders bought bulk active ingredient, often imported. FDA’s September 2025 “green list” import alert made unvetted foreign ingredient much harder to bring in, which pushed that input cost up.
5. Cash-pay only. No insurance billing, no rebates, no pharmacy benefit manager in the middle. Compounded drugs are almost never covered by insurance, which is also a cost to you.

Does insurance change the answer?

Enormously, and in one direction.

If your plan covers a branded GLP-1, your copay will almost always beat any compounded cash price. Platforms that do insurance work — Form Health, knownwell, PlushCare, Teladoc, and Ro’s insurance team — can get medication costs to roughly $25 a month for some patients with a manufacturer savings card [10].

The catch is that coverage has not broadened evenly. GoodRx’s tracking found commercial coverage for GLP-1s became more restrictive for several products in 2026, with tens of millions of people lacking coverage for the newest options [11]. Prior authorization and step therapy are standard.

Compounded product is essentially never covered [12]. That was part of its appeal, and part of its cost.

For Medicare, the picture changed on July 1, 2026, when CMS’s Medicare GLP-1 Bridge Program began [13][18]. Eligible Part D beneficiaries pay a flat $50 monthly copay for Wegovy, the Zepbound KwikPen, or Foundayo. Two details are easy to miss: the program is a time-limited demonstration scheduled to run through December 31, 2027, and the $50 copay sits outside regular Part D, so it does not count toward the deductible or the annual out-of-pocket cap and cannot be reduced by Extra Help. If you are on Medicare and meet the criteria, that is worth checking before anything else.

The part that is not about money

Cost is one axis. Three others belong in the decision.

Evidence. Wegovy’s weight loss results and its cardiovascular outcome data come from trials of that exact product. No compounded version has been through that. FDA has said claims that a compounded product produces identical clinical results are false or misleading [1].

Manufacturing. Branded product is made under an FDA-approved process in inspected facilities. Compounded product has had repeated sterility and particulate recalls, including a roughly 162,000-vial recall by one 503B outsourcing facility in July 2026.

Safety monitoring. With an approved drug there is a legal adverse event reporting chain. State-licensed 503A compounding pharmacies are not required to report adverse events the way manufacturers are, which is why FDA says its tally of more than 1,700 reports naming compounded GLP-1s is likely an undercount.

Legality. The mass-market compounded pathway closed when the shortage ended in February 2025. FDA proposed in April 2026 to permanently exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list; the comment period closed July 30, 2026. Anyone building a year-long plan around compounded supply is building on ground that may move again [14].

How to actually compare two offers

When you have two programs in front of you, normalize them:

1. Add the membership fee to the medication price. Always.
2. Ask whether the price holds as the dose goes up.
3. Check whether the low price requires a prepay, and whether it is refundable.
4. Ask whether labs, shipping, and syringes are included.
5. Ask whether the product is FDA-approved or compounded, and if compounded, which pharmacy makes it.
6. Check your insurance first, even if you assume you are not covered. A single denial letter is cheaper than twelve months of cash payments.
7. Find the cancellation terms before enrolling, not after.

The bottom line

Compounded semaglutide was a rational response to a real shortage and real prices. Both of those conditions changed.

Today, a branded product with trial data behind it, a fixed-dose pen, an FDA-approved manufacturing process, and a real adverse event reporting chain can cost about the same as a compounded vial once you count the membership fee. That does not make the decision for anyone, but it does mean the price argument that carried the compounded market in 2024 no longer carries it by itself.

Whether a GLP-1 is appropriate for you, and which one, is a conversation for a healthcare provider. What this article can tell you is that it is worth having that conversation with the current prices in hand rather than the ones you remember.

Sources

1. FDA to Telehealth Companies: What to Know When Promoting Compounded Drugs — FDA
2. FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss — FDA
3. Wegovy (semaglutide) Online Pharmacy self-pay offer — NovoCare Pharmacy
4. Costco Members Can Now Get Half-Priced Ozempic & Wegovy Prescriptions Through Sesame — Sesame
5. Trump, Eli Lilly, Novo Nordisk unveil deals to cut obesity drug prices — CNBC
6. Trump announces deal with Lilly, Novo to expand access to weight loss drugs, cut prices — STAT News
7. Lilly Reduces Price of Zepbound Single-Dose Vials for Self-Pay Patients — Pharmaceutical Executive
8. Compounded Semaglutide for Weight Loss — Mochi Health
9. Compounded Semaglutide & Tirzepatide Pricing — Ivím Health
10. Weight Loss — Ro Body Membership
11. Live Updates: Insurance Coverage for GIP and GLP-1 Agonists in 2026 — GoodRx Research
12. Are Compounded GLP-1s Going Away? Not Entirely — GoodRx
13. Medicare Coverage for GLP-1 Weight Loss Drugs — knownwell
14. FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List — FDA
15. Novo’s Wegovy pill makes US debut at $149 per month for cash-paying patients — Fierce Pharma
16. Telehealth for Obesity — LillyDirect
17. Novo Nordisk announces significant reduction in US list price for Wegovy, Ozempic, and Rybelsus — Novo Nordisk, February 24, 2026
18. Coming Soon: CMS to Provide $50 Monthly Access to GLP-1 Medications for Medicare Beneficiaries — CMS
19. Type 2 diabetes: New Ozempic pill now available in the U.S. — Medical News Today, May 5, 2026